

# George Nesr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1027955/publications.pdf>

Version: 2024-02-01

12  
papers

66  
citations

1684188

5  
h-index

1588992

8  
g-index

13  
all docs

13  
docs citations

13  
times ranked

103  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma cell leukaemia with "lymphoid" like morphology in peripheral blood. International Journal of Laboratory Hematology, 2022, 44, 10-12.	1.3	2
2	Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience. Journal of Medical Virology, 2022, 94, 1274-1276.	5.0	2
3	Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom. Leukemia and Lymphoma, 2021, 62, 469-472.	1.3	7
4	Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust. Leukemia and Lymphoma, 2021, , 1-4.	1.3	1
5	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 193, 346-355.	2.5	18
6	Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naïve chronic lymphocytic leukaemia: a case report. British Journal of Haematology, 2020, 190, e326-e328.	2.5	6
7	Platelet function in patients with chronic myeloid leukemia treated with asciminib. Leukemia and Lymphoma, 2020, 61, 3021-3023.	1.3	1
8	Immune thrombocytopenia flare with mild COVID-19 infection in pregnancy: A case report. British Journal of Haematology, 2020, 190, e146-e148.	2.5	12
9	The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. Leukemia and Lymphoma, 2019, 60, 3333-3334.	1.3	2
10	T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report. Journal of Clinical Pathology, 2019, 72, 511-512.	2.0	1
11	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica, 2019, 104, 2206-2214.	3.5	10
12	Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients. Blood, 2018, 132, 3007-3007.	1.4	4